Seeking Alpha

Mike Havrilla » Comments » ACUR

  • Pending FDA Decisions: 20 Extreme Trades  [View article]
    DSCO does not currently have a pending application at the FDA and has not provided an update yet following their meeting with the agency to discuss the latest CRL for Surfaxin:

    WARRINGTON, Pa., May 11, 2009 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO - News) has received written notification from the U.S. Food and Drug Administration (FDA) that an end-of-review meeting has been scheduled for June 2, 2009 at the FDA offices in Rockville, Maryland. The purpose of this meeting is to determine the resolution of the remaining primary issue necessary for Discovery Labs to gain U.S. marketing approval of Surfaxin(r) (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants.

    On April 17, 2009, Discovery Labs received a Complete Response letter from the FDA for Surfaxin for RDS. In its letter, the FDA focused primarily on certain aspects of a Surfaxin biological activity test (BAT, a quality control stability and release test) that must be addressed before Surfaxin can be approved. The FDA questioned whether the BAT can adequately distinguish change in Surfaxin drug product over time and whether Discovery Labs has adequately validated the BAT and determined its final acceptance criteria. Discovery Labs intends to rely on data already submitted to the FDA, as well as limited existing data, to support the comparability of Surfaxin clinical drug product to commercial Surfaxin drug product and demonstrate that the BAT can adequately distinguish change in Surfaxin over time and is an appropriate test for monitoring Surfaxin biological activity throughout shelf-life.

    Following the meeting and receipt of formal written minutes from the FDA, Discovery Labs intends to provide an update regarding the outcome and anticipated timeline to potential approval of Surfaxin.



    On Jun 24 01:40 PM thegoodking wrote:

    > I see that DSCO(Discovery Labs) is missing in thhe list. Their drug
    > is in its final stages and FDA is waiting on the quality test(seekingalpha.com/symbo...)
    > which tests its shelf life.
    Jun 24 14:12 pm |Rating: 0 0 |Link to Comment
More on ACUR by Mike Havrilla
Comments by Ticker
AAWW, ABIO, ABMD, ABT, ABX, ACAD, ACCP.OB, ACHN, ACLI, ACOR, ACTC.PK, ACUR, ACUS, ADLR, ADLS, ADLS.OB, AEZS, AFFX, AGEN, AGF, AGN, AHBIF.PK, AIQ, AIS, ALEX, ALGT, ALKS, ALO, ALPMF.PK, ALTH, ALV, ALVR, AMAG, AMGN, AMR, AMX, ANDS, ANPI, APPA, APPX, ARDM.OB, ARIA, ARKTF.PK, ARNA, ARQL, ARYX, ASO, ASTM, ATHX, ATSI,
Mike Havrilla's
Comments Stats
172 comments
Rating: 27 (48 - 21 )